SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2791-2793. Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-04-019836. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-04-019836v1 109/7/2791    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Carpenter, P. A. Articles by Radich, J. P. Search for Related Content PubMed PubMed Citation Articles by Carpenter, P. A. Articles by Radich, J. P. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemia Paul A. Carpenter1,2, David S. Snyder3, Mary E. D. Flowers1, Jean E. Sanders1,2, Theodore A. Gooley1, Paul J. Martin1, Frederick R. Appelbaum1, and Jerald P. Radich1 1 Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA; 2 Departments of Pediatrics and Medicine, University of Washington, Seattle; 3 City of Hope Medical Center, Duarte, CA Relapse occurs frequently after allogeneic hematopoietic cell transplantation (HCT) for treatment of high-risk Philadelphia chromosome–positive (Ph+) leukemia. Administration of imatinib early after HCT might provide an effective approach for preventing recurrent Ph+ leukemia, but the feasibility of this approach has not been systematically tested. Twenty-two patients, 15 with Ph+ acute lymphoblastic leukemia and 7 with high-risk chronic myelogenous leukemia, were enrolled in a prospective study and given imatinib from the time of engraftment until 365 days after HCT. Before day 90, adults (n = 19) tolerated a median average daily imatinib dose of 400 mg/d (range, 200-500 mg/d), and children (n = 3) tolerated 265 mg/m2/d (range, 200-290 mg/m2/d). The most common adverse events related to imatinib administration were grade 1-3 nausea, emesis, and serum transaminase elevations. We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. R. Appelbaum Indications for Hematopoietic Cell Transplantation for the Treatment of Adult Acute Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 325 - 329. [Abstract] [Full Text] [PDF] E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia Blood, December 15, 2007; 110(13): 4614 - 4617. [Abstract] [Full Text] [PDF] J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF] D. A. Thomas Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges Hematology, January 1, 2007; 2007(1): 435 - 443. [Abstract] [Full Text] [PDF] H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020